Simeprevir相关论文
目的:随着聚乙二醇干扰素及利巴韦林(PR)联合丙型肝炎病毒(HCV)蛋白酶抑制剂三联(Triple)方案抗病毒治疗开始应用于基因1b亚型的慢......
2-甲基-3-硝基苯酚经甲基化、傅-克酰化和硝基还原反应得2-甲基-3-氨基-4-乙酰基苯甲醚(2).3-甲基-2-丁酮经溴代、环合、Sandmeyer......
期刊
为探究吕家坨井田地质构造格局,根据钻孔勘探资料,采用分形理论和趋势面分析方法,研究了井田7......
The effectiveness of hepatitis C treatment has improved with the development of interferon(IFN),and it has drastically i......
Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predict
AIM To gather data on the antiviral efficacy and safety of second generation direct acting antiviral(DAA) treatment with......
Managing Hepatitis C Patients in Greece: A Budget Impact Analysis of Simeprevir plus Pegylated Inter
Objectives: To identify local resource use such as pharmaceutical treatment, medical follow-up, and patient hospitalizat......
丙型肝炎病毒是一种肝脏血液产生的感染疾病，会导致显著的肝损伤，包括肝硬化，肝脏出现严重疤痕。慢性丙型肝炎增加肝硬化并发症风险，可......
Hepatitis C virus reinfection after liver transplant： New chances and new challenges in the era of d
The first interferon-free regimens have been approvedfor the treatment of patients with chronic hepatitisC virus （HCV）. In......
Chronic hepatitis C infection is the leading cause ofchronic liver disease, cirrhosis, hepatocellular carcinomaas well a......
AIM To compare efficacy of telaprevir （TVR） andsimeprevir （SMV） combined with pegylated interferon（PEG-IFN） and ribavirin （RBV） ......
Efficacy and safety of telaprevir- and simeprevir-based triple therapies for older patients with chr
AIM To evaluate and compare the efficacy and safety of telaprevir(TVR)-and simeprevir(SMV)-based triple therapies in eld......
Re-re-treatment of hepatitis C virus: Eight patients who relapsed twice after direct-acting-antivira
AIM: To determine risk factors associated with hepatitis C virus(HCV) treatment failure after direct acting antivirals i......
The year 2014 marked the beginning of the end of the interferon era and the triumph of the all-oral interferon-free regi......
<正>Simeprevir(TMC-435,1),化学名为(2R,3aR,10Z,11aS,12aR,14aR)-N-(环丙磺酰基)-2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-十四氢-......
(3R,4R)-3,4-二甲酸甲酯环戊酮（CAS：35079-19-7）是合成simeprevir的关键中间体，本文通过应用PLE（猪肝酯酶）的选择性水解，建立了合成(3R,4R......
